Amedeo Smart

Free Medical Literature Service


 

Amedeo

Breast Cancer

  Free Subscription

Articles published in
Cancer Res
    February 2025
  1. METGE BJ, Williams L, Swain CA, Hinshaw DC, et al
    Ribosomal RNA Biosynthesis Functionally Programs Tumor-Associated Macrophages to Support Breast Cancer Progression.
    Cancer Res. 2025 Feb 4. doi: 10.1158/0008-5472.CAN-24-0707.
    >> Share

  2. MADORSKY ROWDO FP, Martini R, Ackermann SE, Tang CP, et al
    Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition.
    Cancer Res. 2025;85:551-566.
    >> Share

  3. TREMBATH HE, Spanheimer PM
    In Search of Representative Translational Cancer Model Systems.
    Cancer Res. 2025;85:407-409.
    >> Share

    January 2025
  4. TABET I, Orhan E, Candiello E, Fenou L, et al
    Replication-Poison Treatment in BRCA1-Deficient Breast Cancer Causes MRE11 Over-Resection that Induces Single-Stranded DNA Accumulation and Mitotic Catastrophe.
    Cancer Res. 2025 Jan 29. doi: 10.1158/0008-5472.CAN-24-1404.
    >> Share

  5. VAN ALSTEN SC, Love MI, Calhoun BC, Butler EN, et al
    Genomic Analysis Reveals Racial and Age-Related Differences in the Somatic Landscape of Breast Cancer and the Association with Socioeconomic Factors.
    Cancer Res. 2025 Jan 29. doi: 10.1158/0008-5472.CAN-24-1788.
    >> Share

  6. VISAL TH, Bayraktar R, den Hollander P, Attathikhun MA, et al
    Accumulation of CD38 in Hybrid Epithelial/Mesenchymal Cells Promotes Immune Remodeling and Metastasis in Breast Cancer.
    Cancer Res. 2025 Jan 24:OF1-OF18. doi: 10.1158/0008-5472.CAN-24-0400.
    >> Share

  7. PIERRO EW, Cottam MA, An H, Lehmann BD, et al
    Comparison of Lean, Obese, and Weight Loss Models Reveals TREM2 Deficiency Attenuates Breast Cancer Growth Uniquely in Lean Mice and Alters Clonal T Cell Populations.
    Cancer Res. 2025 Jan 22. doi: 10.1158/0008-5472.CAN-24-3511.
    >> Share

  8. GAO L, Huang J, Xia J, Zhao P, et al
    SNHG17 Reprograms Energy Metabolism of Breast Cancer by Activating Mitochondrial DNAs Transcription.
    Cancer Res. 2025 Jan 22. doi: 10.1158/0008-5472.CAN-24-1271.
    >> Share

  9. TAU S, Chamberlin MD, Yang H, Marotti JD, et al
    Oxidative Phosphorylation is a Metabolic Vulnerability of Endocrine Therapy-Tolerant Persister Cells in ER+ Breast Cancer.
    Cancer Res. 2025 Jan 9. doi: 10.1158/0008-5472.CAN-24-1204.
    >> Share

    December 2024
  10. CHEN SY, He PL, Lu LY, Lin MC, et al
    ST6GAL1-Mediated Sialylation of PECAM-1 Promotes a Transcellular Diapedesis-Like Process that Directs Lung Tropism of Metastatic Breast Cancer.
    Cancer Res. 2024 Dec 30. doi: 10.1158/0008-5472.CAN-24-1550.
    >> Share

  11. CHEN F, Ding K, Priedigkeit N, Elangovan A, et al
    Correction: Single-Cell Transcriptomic Heterogeneity in Invasive Ductal and Lobular Breast Cancer Cells.
    Cancer Res. 2024;84:4298.
    >> Share

  12. FENG JR, Li X, Han C, Chang Y, et al
    C-Reactive Protein Induces Immunosuppression by Activating FcgammaR2B in Pulmonary Macrophages to Promote Lung Metastasis.
    Cancer Res. 2024;84:4184-4198.
    >> Share

  13. SHI W, Li L, Zhao H, Li Z, et al
    Targeting SHCBP1 Inhibits Tumor Progression by Restoring Ciliogenesis in Ductal Carcinoma.
    Cancer Res. 2024;84:4156-4172.
    >> Share

  14. BHAGWAT SV, Mur C, Vandekopple M, Zhao B, et al
    Imlunestrant is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wildtype and Mutant Breast Cancer.
    Cancer Res. 2024 Dec 9. doi: 10.1158/0008-5472.CAN-24-2608.
    >> Share

  15. FRIELING JS, Lynch CC
    Tales of Cancer-Induced Bone Disease from the Senescent Osteocyte Crypt.
    Cancer Res. 2024;84:3917-3918.
    >> Share

    November 2024
  16. JIANG WJ, Zhou TH, Huang HJ, Li LS, et al
    Breast Cancer Subtype-Specific Organotropism is Dictated by FOXF2-Regulated Metastatic Dormancy and Recovery.
    Cancer Res. 2024 Nov 26. doi: 10.1158/0008-5472.CAN-24-0479.
    >> Share

  17. ZENG W, Zhang R, Huang P, Chen M, et al
    Ferroptotic Neutrophils Induce Immunosuppression and Chemoresistance in Breast Cancer.
    Cancer Res. 2024 Nov 12. doi: 10.1158/0008-5472.CAN-24-1941.
    >> Share

  18. SHEA A, Eyal-Lubling Y, Guerrero-Romero D, Manzano Garcia R, et al
    Modeling Drug Responses and Evolutionary Dynamics using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple Negative Breast Cancer.
    Cancer Res. 2024 Nov 8. doi: 10.1158/0008-5472.CAN-24-1703.
    >> Share

    October 2024
  19. KUETT L, Bollhagen A, Tietscher S, Sobottka B, et al
    Distant Metastases of Breast Cancer Resemble Primary Tumors in Cancer Cell Composition but Differ in Immune Cell Phenotypes.
    Cancer Res. 2024 Oct 22. doi: 10.1158/0008-5472.CAN-24-1211.
    >> Share

  20. CACKOWSKI FC, Korkaya H
    Breast Cancer Disseminated Tumor Cells: Do They Stay and Fight or Run and Hide?
    Cancer Res. 2024;84:3319-3321.
    >> Share

  21. PAREJA F, Dopeso H, Wang YK, Gazzo AM, et al
    A Genomics-Driven Artificial Intelligence-Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating Mechanisms.
    Cancer Res. 2024;84:3478-3489.
    >> Share

  22. FALCONE M, Salhia B, Hughes Halbert C, Roussos Torres ET, et al
    Impact of Structural Racism and Social Determinants of Health on Disparities in Breast Cancer Mortality.
    Cancer Res. 2024 Oct 2. doi: 10.1158/0008-5472.CAN-24-1359.
    >> Share

  23. GEMMA C, Lai CF, Singh AK, Belfiore A, et al
    Induction of the TEAD Co-activator VGLL1 by Estrogen Receptor-Targeted Therapy Drives Resistance in Breast Cancer.
    Cancer Res. 2024 Oct 2. doi: 10.1158/0008-5472.CAN-24-0013.
    >> Share

  24. PURDY SC, Ford HL
    Remembering Hypoxia: Uncovering the Long-Term Effects of Transient Oxygen Deprivation on IFN Signaling and Progression of Breast Cancer.
    Cancer Res. 2024;84:3125-3127.
    >> Share

  25. GONZALEZ ME, Brophy B, Eido A, Leonetti AE, et al
    CCN6 Suppresses Metaplastic Breast Carcinoma by Antagonizing Wnt/beta-Catenin Signaling to Inhibit EZH2-Driven EMT.
    Cancer Res. 2024;84:3235-3249.
    >> Share

  26. SHIN SY, Chew NJ, Ghomlaghi M, Chueh AC, et al
    Integrative Modeling of Signaling Network Dynamics Identifies Cell Type-Selective Therapeutic Strategies for FGFR4-Driven Cancers.
    Cancer Res. 2024;84:3296-3309.
    >> Share

    September 2024
  27. KAUR J, Adhikari M, Sabol HM, Anloague A, et al
    Single-cell Transcriptomic Analysis Identifies Senescent Osteocytes that Trigger Bone Destruction in Breast Cancer Metastasis.
    Cancer Res. 2024 Sep 23. doi: 10.1158/0008-5472.CAN-24-0857.
    >> Share

  28. LUO M, Shen N, Shang L, Fang Z, et al
    Simultaneous Targeting of NQO1 and SOD1 Eradicates Breast Cancer Stem Cells via Mitochondrial Futile Redox Cycling.
    Cancer Res. 2024 Sep 12. doi: 10.1158/0008-5472.CAN-24-0800.
    >> Share

  29. GILKES DM, Chaturvedi P, Bajpai S, Wong CC, et al
    Retraction: Collagen Prolyl Hydroxylases Are Essential for Breast Cancer Metastasis.
    Cancer Res. 2024;84:2927.
    >> Share

  30. SAMANTA D, Park Y, Andrabi SA, Shelton LM, et al
    Retraction: PHGDH Expression Is Required for Mitochondrial Redox Homeostasis, Breast Cancer Stem Cell Maintenance, and Lung Metastasis.
    Cancer Res. 2024;84:2926.
    >> Share

  31. CONNER SJ, Borges HB, Guarin JR, Gerton TJ, et al
    Obesity Induces Temporally Regulated Alterations in the Extracellular Matrix That Drive Breast Tumor Invasion and Metastasis.
    Cancer Res. 2024;84:2761-2775.
    >> Share

    August 2024
  32. ZHOU Z, Si Y, Zhang J, Chen K, et al
    A Dual-Payload Antibody-Drug Conjugate Targeting CD276/B7-H3 Elicits Cytotoxicity and Immune Activation in Triple-Negative Breast Cancer.
    Cancer Res. 2024 Aug 26. doi: 10.1158/0008-5472.CAN-23-4099.
    >> Share

  33. LI YW, Dai LJ, Wu XR, Zhao S, et al
    Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies.
    Cancer Res. 2024 Aug 26. doi: 10.1158/0008-5472.CAN-23-4066.
    >> Share

  34. LEWIS MW, King CM, Wisniewska K, Regner MJ, et al
    CRISPR Screening of Transcribed Super-Enhancers Identifies Drivers of Triple-Negative Breast Cancer Progression.
    Cancer Res. 2024 Aug 26. doi: 10.1158/0008-5472.CAN-23-3995.
    >> Share

  35. LI M, Lulla AR, Wang Y, Tsavachidis S, et al
    Low Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer.
    Cancer Res. 2024 Aug 26. doi: 10.1158/0008-5472.CAN-23-4130.
    >> Share

  36. HEATH J, Mirabelli C, Annis MG, Sabourin V, et al
    The Neurodevelopmental Protein POGZ Suppresses Metastasis in Triple Negative Breast Cancer by Attenuating TGFbeta Signaling.
    Cancer Res. 2024 Aug 13. doi: 10.1158/0008-5472.CAN-23-3887.
    >> Share

  37. BUSHNELL GG, Sharma D, Wilmot HC, Zheng M, et al
    Natural Killer Cell Regulation of Breast Cancer Stem Cells Mediates Metastatic Dormancy.
    Cancer Res. 2024 Aug 6. doi: 10.1158/0008-5472.CAN-24-0030.
    >> Share

    July 2024
  38. WANG X, Qu Y, Xu Q, Jiang Z, et al
    NQO1 Triggers Neutrophil Recruitment and NET formation to Drive Lung Metastasis of Invasive Breast Cancer.
    Cancer Res. 2024 Jul 29. doi: 10.1158/0008-5472.CAN-24-0291.
    >> Share

  39. HSU WJ, Chiang MC, Chao YC, Chang YC, et al
    Arginine methylation of DDX3 by PRMT1 mediates mitochondrial homeostasis to promote breast cancer metastasis.
    Cancer Res. 2024 Jul 23. doi: 10.1158/0008-5472.CAN-23-3829.
    >> Share

  40. PIEMONTE KM, Ingles NN, Weber Bonk KL, Valentine MJ, et al
    Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer.
    Cancer Res. 2024 Jul 22. doi: 10.1158/0008-5472.CAN-23-2558.
    >> Share

  41. HUANG YZ, Sang MY, Xi PW, Xu RX, et al
    FANCI Inhibition Induces PARP1 Redistribution to Enhance the Efficacy of PARP Inhibitors in Breast Cancer.
    Cancer Res. 2024 Jul 22. doi: 10.1158/0008-5472.CAN-23-2738.
    >> Share

  42. HILLIS AL, Martin TD, Manchester HE, Hogstrom J, et al
    Targeting Cholesterol Biosynthesis with Statins Synergizes with AKT Inhibitors in Triple-Negative Breast Cancer.
    Cancer Res. 2024 Jul 18. doi: 10.1158/0008-5472.CAN-24-0970.
    >> Share

  43. IRIONDO O, Mecenas D, Li Y, Chin CR, et al
    Hypoxic Memory Mediates Prolonged Tumor Intrinsic Type I Interferon Suppression to Promote Breast Cancer Progression.
    Cancer Res. 2024 Jul 11. doi: 10.1158/0008-5472.CAN-23-2028.
    >> Share

  44. LEE G, Wong C, Cho A, West JJ, et al
    E-cadherin Induces Serine Synthesis to Support Progression and Metastasis of Breast Cancer.
    Cancer Res. 2024 Jul 3. doi: 10.1158/0008-5472.CAN-23-3082.
    >> Share

    June 2024
  45. MENEGOLLO M, Bentham RB, Henriques T, Ng SQ, et al
    Multi-State Gene Cluster Switches Determine the Adaptive Mitochondrial And Metabolic Landscape of Breast Cancer.
    Cancer Res. 2024 Jun 26. doi: 10.1158/0008-5472.CAN-23-3172.
    >> Share

  46. XU G, Huang R, Wumaier R, Lyu J, et al
    Proteomic Profiling of Serum Extracellular Vesicles Identifies Diagnostic Signatures and Therapeutic Targets in Breast Cancer.
    Cancer Res. 2024 Jun 20. doi: 10.1158/0008-5472.CAN-23-3998.
    >> Share

  47. TUCKER JB, Carlsen CL, Scribano CM, Pattaswamy SM, et al
    CENP-E inhibition induces chromosomal instability and synergizes with diverse microtubule-targeting agents in breast cancer.
    Cancer Res. 2024 Jun 4. doi: 10.1158/0008-5472.CAN-23-3332.
    >> Share

  48. SUN X, Verma SP, Jia G, Wang X, et al
    Case-Case Genome-Wide Analyses Identify Subtype-Informative Variants that Confer Risk for Breast Cancer.
    Cancer Res. 2024 Jun 4. doi: 10.1158/0008-5472.CAN-23-3854.
    >> Share

  49. ELEMENTO O
    How Artificial Intelligence Unravels the Complex Web of Cancer Drug Response.
    Cancer Res. 2024;84:1745-1746.
    >> Share

    May 2024
  50. HUANG MY, Hu SY, Dong J, Deng L, et al
    The DRAP1/DR1 Repressor Complex Increases mTOR Activity to Promote Progression and Confer Everolimus Sensitivity in Triple-Negative Breast Cancer.
    Cancer Res. 2024 May 15. doi: 10.1158/0008-5472.CAN-23-2781.
    >> Share

    April 2024
  51. XIA J, Zhang L, Peng X, Tu J, et al
    IL1R2 blockade alleviates immunosuppression and potentiates anti-PD-1 efficacy in triple-negative breast cancer.
    Cancer Res. 2024 Apr 24. doi: 10.1158/0008-5472.CAN-23-3429.
    >> Share

  52. ZHENG SM, Feng YC, Zhu Q, Li RQ, et al
    MILIP Binding to tRNAs Promotes Protein Synthesis to Drive Triple-Negative Breast Cancer.
    Cancer Res. 2024 Apr 9:OF1-OF15. doi: 10.1158/0008-5472.CAN-23-3046.
    >> Share

    March 2024
  53. ZHANG M, Zhou K, Wang Z, Liu T, et al
    A subpopulation of luminal progenitors secretes pleiotrophin to promote angiogenesis and metastasis in inflammatory breast cancer.
    Cancer Res. 2024 Mar 20. doi: 10.1158/0008-5472.CAN-23-2640.
    >> Share

  54. QIU Y, Wang X, Sun Y, Jin T, et al
    ACSL4-mediated membrane phospholipid remodeling induces integrin beta1 activation to facilitate triple-negative breast cancer metastasis.
    Cancer Res. 2024 Mar 12. doi: 10.1158/0008-5472.CAN-23-2491.
    >> Share

    February 2024
  55. YAMAMOTO T, Hayashida T, Masugi Y, Oshikawa K, et al
    PRMT1 sustains de novo fatty acid synthesis by methylating PHGDH to drive chemoresistance in triple-negative breast cancer.
    Cancer Res. 2024 Feb 22. doi: 10.1158/0008-5472.CAN-23-2266.
    >> Share

  56. YAN L, Wu M, Wang T, Yuan H, et al
    Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming that Drives Immune Evasion.
    Cancer Res. 2024 Feb 9. doi: 10.1158/0008-5472.CAN-23-2390.
    >> Share

  57. BERNARD MJ, Goldstein AS
    A metabolic-epigenetic mechanism directs cell fate and therapeutic sensitivity in breast cancer.
    Cancer Res. 2024 Feb 8. doi: 10.1158/0008-5472.CAN-24-0460.
    >> Share

  58. GEDIK ME, Saatci O, Oberholtzer N, Uner M, et al
    Targeting TACC3 induces immunogenic cell death and enhances T-DM1 response in HER2-positive breast cancer.
    Cancer Res. 2024 Feb 6. doi: 10.1158/0008-5472.CAN-23-2812.
    >> Share

    January 2024
  59. MARQUEZ-PALENCIA M, Reza Herrera L, Parida PK, Ghosh S, et al
    AXL/WRNIP1 mediates replication stress response and promotes therapy resistance and metachronous metastasis in HER2+ breast cancer.
    Cancer Res. 2024 Jan 8. doi: 10.1158/0008-5472.CAN-23-1459.
    >> Share

  60. SOOSAINATHAN A, Iravani M, El-Botty R, Alexander J, et al
    Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers.
    Cancer Res. 2024;84:17-25.
    >> Share

    December 2023
  61. KIM S, Oh J, Park C, Kim M, et al
    FAM3C in cancer-associated adipocytes promotes breast cancer cell survival and metastasis.
    Cancer Res. 2023 Dec 20. doi: 10.1158/0008-5472.CAN-23-1641.
    >> Share

  62. LIN P, Lourenco C, Cruickshank J, Palomero L, et al
    Topoisomerase 1 Inhibition in MYC-Driven Cancer Promotes Aberrant R-Loop Accumulation to Induce Synthetic Lethality.
    Cancer Res. 2023;83:4015-4029.
    >> Share

  63. COMPTON ZT, Mallo D, Maley CC
    Stronger Together: Cancer Clones Cooperate to Alleviate Growth Barriers in Critical Cancer Progression Transitions.
    Cancer Res. 2023;83:4013-4014.
    >> Share

  64. MICHAUD DE, Guerriero JL
    Myeloid cells pave the metastatic road in breast cancer.
    Cancer Res. 2023 Dec 6. doi: 10.1158/0008-5472.CAN-23-3803.
    >> Share

  65. FAN H, Xu Z, Yao K, Zheng B, et al
    Osteoclast-Cancer Cell Metabolic Crosstalk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer.
    Cancer Res. 2023 Dec 1. doi: 10.1158/0008-5472.CAN-23-1443.
    >> Share

    November 2023
  66. WALL SW, Echeverria GV
    Avoiding Extinction: Cancer-Associated Fibroblasts Help Triple-Negative Breast Cancer Outrun Chemotherapy.
    Cancer Res. 2023;83:3667-3669.
    >> Share

  67. XU Y, Li X, Zhang S, Tang M, et al
    CircMMP2(6,7) cooperates with beta-catenin and PRMT5 to disrupt bone homeostasis and promote breast cancer bone metastasis.
    Cancer Res. 2023 Nov 14. doi: 10.1158/0008-5472.CAN-23-1899.
    >> Share

    October 2023
  68. AHN S, Park JH, Grimm SL, Piyarathna DWB, et al
    Metabolomic rewiring promotes endocrine therapy resistance in breast cancer.
    Cancer Res. 2023 Oct 31. doi: 10.1158/0008-5472.CAN-23-0184.
    >> Share

  69. JACOBS C, Shah S, Lu WC, Ray H, et al
    HSF1 inhibits antitumor immune activity in breast cancer by suppressing CCL5 to block CD8+ T cell recruitment.
    Cancer Res. 2023 Oct 27. doi: 10.1158/0008-5472.CAN-23-0902.
    >> Share

  70. MIROSHNYCHENKO D, Miti T, Kumar P, Miller A, et al
    Stroma-mediated breast cancer cell proliferation indirectly drives chemoresistance by accelerating tumor recovery between chemotherapy cycles.
    Cancer Res. 2023 Oct 4. doi: 10.1158/0008-5472.CAN-23-0398.
    >> Share

  71. WU J, Subbiah V
    RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond.
    Cancer Res. 2023;83:3159-3161.
    >> Share

  72. WINGATE HF, Keyomarsi K
    Distinct Mechanisms of Resistance to CDK4/6 Inhibitors Require Specific Subsequent Treatment Strategies: One Size Does Not Fit All.
    Cancer Res. 2023;83:3165-3167.
    >> Share

  73. NAVARRO-YEPES J, Kettner NM, Rao X, Bishop CS, et al
    Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers.
    Cancer Res. 2023;83:3264-3283.
    >> Share

    September 2023
  74. LAWSON M, Cureton N, Ros S, Cheraghchi-Bashi-Astaneh A, et al
    The next-generation oral selective estrogen receptor degrader camizestrant (AZD9833) suppresses ER+ breast cancer growth and overcomes endocrine and CDK4/6 inhibitor resistance.
    Cancer Res. 2023 Sep 19. doi: 10.1158/0008-5472.CAN-23-0694.
    >> Share

  75. MUKHERJEE D, Previs RA, Haines C, Al Abo M, et al
    Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis.
    Cancer Res. 2023;83:2889-2907.
    >> Share

    August 2023
  76. COHEN N, Mundhe D, Deasy SK, Adler O, et al
    Breast cancer-secreted factors promote lung metastasis by signaling systemically to induce a fibrotic pre-metastatic niche.
    Cancer Res. 2023 Aug 7:CAN-22-3707. doi: 10.1158/0008-5472.CAN-22-3707.
    >> Share

  77. ZHU YY, Song L, Zhang YQ, Liu WL, et al
    Development of a rare earth nanoprobe enables in vivo real-time detection of sentinel lymph node metastasis of breast cancer using NIR-IIb imaging.
    Cancer Res. 2023 Aug 4:CAN-22-3432. doi: 10.1158/0008-5472.CAN-22-3432.
    >> Share

  78. MATHUR D, Liao C, Lin W, La Ferlita A, et al
    The ratio of key metabolic transcripts is a predictive biomarker of breast cancer metastasis to the lung.
    Cancer Res. 2023 Aug 1:CAN-23-0153. doi: 10.1158/0008-5472.CAN-23-0153.
    >> Share

  79. SCHMIT SL, Purrington K, Figueiredo JC
    Efforts to Grow Genomic Research in Ancestrally Diverse and Admixed Populations.
    Cancer Res. 2023;83:2443-2444.
    >> Share

  80. HU C, Nagaraj AB, Shimelis H, Montalban G, et al
    Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C.
    Cancer Res. 2023;83:2557-2571.
    >> Share

  81. SHU X, Li J, Chan UI, Su SM, et al
    BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance.
    Cancer Res. 2023;83:2614-2633.
    >> Share

  82. DING YC, Song H, Adamson AW, Schmolze D, et al
    Profiling the Somatic Mutational Landscape of Breast Tumors from Hispanic/Latina Women Reveals Conserved and Unique Characteristics.
    Cancer Res. 2023;83:2600-2613.
    >> Share

    July 2023
  83. AMAYA RAMIREZ CC, Loayza-Puch F
    Breast Cancer Metastatic Progression Requires mRNA Posttranscriptional Suppression.
    Cancer Res. 2023 Jul 19:OF1-OF2. doi: 10.1158/0008-5472.CAN-23-1729.
    >> Share

  84. WANG Z, Zhang N, Zhang M, Jiang Y, et al
    GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner.
    Cancer Res. 2023 Jul 18:CAN-22-3471. doi: 10.1158/0008-5472.CAN-22-3471.
    >> Share

  85. YU S, Wang Y, Gong X, Fan Z, et al
    LncRNA AGPG confers endocrine resistance in breast cancer by promoting E2F1 activity.
    Cancer Res. 2023 Jul 18:CAN-23-0015. doi: 10.1158/0008-5472.CAN-23-0015.
    >> Share

  86. HERMIDA-PRADO F, Xie Y, Sherman S, Nagy Z, et al
    Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer.
    Cancer Res. 2023 Jul 14:CAN-23-1711. doi: 10.1158/0008-5472.CAN-23-1711.
    >> Share

  87. ACETO N, Gvozdenovic A
    Metastasis Unleashed: Hyposialylation Empowers Chemo-Evasive Circulating Tumor Cell Clusters in Breast Cancer.
    Cancer Res. 2023 Jul 7:CAN-23-1978. doi: 10.1158/0008-5472.CAN-23-1978.
    >> Share

  88. MARIN A, Mamun AA, Patel H, Akamatsu H, et al
    Acquired secondary HER2 mutations enhance HER2/MAPK signaling and promote resistance to HER2 kinase inhibition in breast cancer.
    Cancer Res. 2023 Jul 5:CAN-22-3617. doi: 10.1158/0008-5472.CAN-22-3617.
    >> Share

  89. NULL JL, Kim DJ, McCann JV, Pramoonjago P, et al
    Periostin+ Stromal Cells Guide Lymphovascular Invasion by Cancer Cells.
    Cancer Res. 2023;83:2105-2122.
    >> Share

  90. KA NL, Park MK, Kim SS, Jeon Y, et al
    NR1D1 stimulates antitumor immune responses in breast cancer by activating cGAS-STING signaling.
    Cancer Res. 2023 Jul 3:CAN-23-0329. doi: 10.1158/0008-5472.CAN-23-0329.
    >> Share

    June 2023
  91. FATTORI S, Le Roy A, Houacine J, Robert L, et al
    CD25high Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer.
    Cancer Res. 2023 Jun 28:CAN-23-0613. doi: 10.1158/0008-5472.CAN-23-0613.
    >> Share

  92. LI B, Qi F, Zhu F, Lu Z, et al
    Nanoparticle-based combination therapy enhances fulvestrant efficacy and overcomes tumor resistance in ER-positive breast cancer.
    Cancer Res. 2023 Jun 16:CAN-22-3559. doi: 10.1158/0008-5472.CAN-22-3559.
    >> Share

  93. JAILKHANI N, Clauser KR, Mak HH, Rickelt S, et al
    Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases.
    Cancer Res. 2023;83:2052-2065.
    >> Share

  94. LI Z, Li T, Yates ME, Wu Y, et al
    The EstroGene database reveals diverse temporal, context-dependent, and bidirectional estrogen receptor regulomes in breast cancer.
    Cancer Res. 2023 Jun 5:CAN-23-0539. doi: 10.1158/0008-5472.CAN-23-0539.
    >> Share

  95. CHENG X, Sun Y, Highkin M, Vemalapally N, et al
    Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 -Cyclin D1 axis driving tumorigenesis and drug resistance.
    Cancer Res. 2023 Jun 5:CAN-22-3558. doi: 10.1158/0008-5472.CAN-22-3558.
    >> Share

    May 2023
  96. RODA N, Cossa A, Hillje R, Tirelli A, et al
    A rare subset of primary tumor cells with concomitant hyper-activation of extracellular matrix remodeling and dsRNA-IFN1 signaling metastasizes in breast cancer.
    Cancer Res. 2023 May 3:CAN-22-2717. doi: 10.1158/0008-5472.CAN-22-2717.
    >> Share

  97. PENG WT, Jin X, Xu XE, Yang YS, et al
    Inhibition of ACAA1 Restrains Proliferation and Potentiates the Response to CDK4/6 Inhibitors in Triple-Negative Breast Cancer.
    Cancer Res. 2023 May 2:OF1-OF14. doi: 10.1158/0008-5472.CAN-22-2143.
    >> Share

    April 2023
  98. GOU X, Kim BJ, Anurag M, Lei JT, et al
    Kinome reprogramming is a targetable vulnerability in ESR1 fusion-driven breast cancer.
    Cancer Res. 2023 Apr 18:CAN-22-3484. doi: 10.1158/0008-5472.CAN-22-3484.
    >> Share

  99. LU XX, Yang WX, Pei YC, Luo H, et al
    An in vivo CRISPR screen identifies that SNRPC promotes triple-negative breast cancer progression.
    Cancer Res. 2023 Apr 14:CAN-22-0536. doi: 10.1158/0008-5472.CAN-22-0536.
    >> Share

  100. KHATPE AS, Dirks R, Bhat-Nakshatri P, Mang H, et al
    TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer.
    Cancer Res. 2023;83:1345-1360.
    >> Share

  101. SUN Z, Jiang Q, Gao B, Zhang X, et al
    AKT Blocks SIK1-Mediated Repression of STAT3 to Promote Breast Tumorigenesis.
    Cancer Res. 2023;83:1264-1279.
    >> Share

    March 2023
  102. SALVADOR F, Martin A, Lopez-Menendez C, Moreno-Bueno G, et al
    Correction: Lysyl Oxidase-like Protein LOXL2 Promotes Lung Metastasis of Breast Cancer.
    Cancer Res. 2023;83:974.
    >> Share

    February 2023
  103. MALIK N, Kim YI, Yan H, Tseng YC, et al
    Dysregulation of mitochondrial translation caused by CBFB deficiency cooperates with mutant PIK3CA and is a vulnerability in breast cancer.
    Cancer Res. 2023 Feb 14:CAN-22-2525. doi: 10.1158/0008-5472.CAN-22-2525.
    >> Share

    January 2023
  104. ANSTINE LJ, Majmudar PR, Aponte A, Singh S, et al
    TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis.
    Cancer Res. 2023 Jan 25:CAN-22-3133. doi: 10.1158/0008-5472.CAN-22-3133.
    >> Share

  105. DAS C, Adhikari S, Bhattacharya A, Chakraborty S, et al
    Epigenetic-Metabolic Interplay in the DNA Damage Response and Therapeutic Resistance of Breast Cancer.
    Cancer Res. 2023 Jan 18:CAN-22-3015. doi: 10.1158/0008-5472.CAN-22-3015.
    >> Share

    December 2022
  106. WEIGEL C, Maczis MA, Palladino END, Green CD, et al
    Sphingosine kinase 2 in stromal fibroblasts creates a hospitable tumor microenvironment in breast cancer.
    Cancer Res. 2022 Dec 21:CAN-22-1638. doi: 10.1158/0008-5472.CAN-22-1638.
    >> Share

  107. LIAO L, Zhang YL, Deng L, Chen C, et al
    Protein phosphatase 1 subunit PPP1R14B stabilizes STMN1 to promote progression and paclitaxel resistance in triple-negative breast cancer.
    Cancer Res. 2022 Dec 9:CAN-22-2709. doi: 10.1158/0008-5472.CAN-22-2709.
    >> Share

  108. WEI L, Gao H, Yu J, Zhang H, et al
    Pharmacological targeting of androgen receptor elicits context-specific effects in estrogen receptor-positive breast cancer.
    Cancer Res. 2022 Dec 5:CAN-22-1016. doi: 10.1158/0008-5472.CAN-22-1016.
    >> Share

    November 2022
  109. STEVENS LE, Peluffo G, Qiu X, Temko D, et al
    JAK-STAT signaling in inflammatory breast cancer enables chemotherapy-resistant cell states.
    Cancer Res. 2022 Nov 21:CAN-22-0423. doi: 10.1158/0008-5472.CAN-22-0423.
    >> Share

  110. WANG F, Moon W, Letsou W, Sapkota Y, et al
    Genome-wide Analysis of Rare Haplotypes Associated with Breast Cancer Risk.
    Cancer Res. 2022 Nov 10. pii: 710536. doi: 10.1158/0008-5472.CAN-22-1888.
    >> Share

  111. GONG P, Chin SL, Allen WM, Ballal H, et al
    Quantitative Micro-Elastography Enables In Vivo Detection of Residual Cancer in the Surgical Cavity during Breast-Conserving Surgery.
    Cancer Res. 2022;82:4093-4104.
    >> Share

  112. PERRONE M, Chiodoni C, Lecchi M, Botti L, et al
    ATF3 reprograms the bone marrow niche in response to early breast cancer transformation.
    Cancer Res. 2022 Nov 1. pii: 710151. doi: 10.1158/0008-5472.CAN-22-0651.
    >> Share

    October 2022
  113. HALPERIN C, Hey J, Weichenhan D, Stein Y, et al
    Global DNA Methylation Analysis of Cancer-Associated Fibroblasts Reveals Extensive Epigenetic Rewiring Linked with RUNX1 Upregulation in Breast Cancer Stroma.
    Cancer Res. 2022 Oct 26:OF1-OF14. doi: 10.1158/0008-5472.CAN-22-0209.
    >> Share

  114. BASSIOUNI R, Idowu MO, Gibbs LD, Robila V, et al
    Spatial transcriptomic analysis of a diverse patient cohort reveals a conserved architecture in triple-negative breast cancer.
    Cancer Res. 2022 Oct 25. pii: 710045. doi: 10.1158/0008-5472.CAN-22-2682.
    >> Share

  115. HARGROVE-WILEY E, Fingleton B
    Sex hormones in breast cancer immunity.
    Cancer Res. 2022 Oct 24. pii: 709945. doi: 10.1158/0008-5472.CAN-22-1829.
    >> Share

  116. TARANTINO P, Tolaney SM
    The Dawn of the Antibody-Drug Conjugates Era: How T-DM1 Reinvented the Future of Chemotherapy for Solid Tumors.
    Cancer Res. 2022;82:3659-3661.
    >> Share

  117. BLAWSKI R, Toska E
    A Unique FOXA1-Associated Chromatin State Dictates Therapeutic Resistance in Lobular Breast Cancer.
    Cancer Res. 2022;82:3668-3670.
    >> Share

  118. DURO-SANCHEZ S, Nadal-Serrano M, Lalinde-Gutierrez M, Arenas EJ, et al
    Therapy-induced senescence enhances the efficacy of HER2-targeted antibody-drug conjugates in breast cancer.
    Cancer Res. 2022 Oct 12. pii: 709715. doi: 10.1158/0008-5472.CAN-22-0787.
    >> Share

  119. HONG J, Lee JH, Zhang Z, Wu Y, et al
    PRC2-mediated epigenetic suppression of type I IFN-STAT2 signaling impairs antitumor immunity in luminal breast cancer.
    Cancer Res. 2022 Oct 12. pii: 709714. doi: 10.1158/0008-5472.CAN-22-0736.
    >> Share

  120. ELKHOLI IE, Lalonde A, Park M, Cote JF, et al
    Breast Cancer Metastatic Dormancy and Relapse: An enigma of microenvironment(s).
    Cancer Res. 2022 Oct 10. pii: 709673. doi: 10.1158/0008-5472.CAN-22-1902.
    >> Share

    September 2022
  121. TOKURA M, Nakayama J, Prieto-Vila M, Shiino S, et al
    Single-Cell Transcriptome Profiling Reveals Intratumoral Heterogeneity and Molecular Features of Ductal Carcinoma In Situ.
    Cancer Res. 2022;82:3236-3248.
    >> Share

  122. LIU H, Lyu H, Jiang G, Chen D, et al
    ALKBH5-mediated m6A demethylation of GLUT4 mRNA promotes glycolysis and resistance to HER2-targeted therapy in breast cancer.
    Cancer Res. 2022 Sep 7. pii: 709106. doi: 10.1158/0008-5472.CAN-22-0800.
    >> Share

    August 2022
  123. FATTORI S, Roux H, Connen E, Robert L, et al
    Therapeutic targeting of tumor-infiltrating regulatory T cells in breast cancer.
    Cancer Res. 2022 Aug 30. pii: 708918. doi: 10.1158/0008-5472.CAN-22-0654.
    >> Share

  124. GUO Q, Wang H, Duan J, Luo W, et al
    An alternatively spliced p62 isoform confers resistance to chemotherapy in breast cancer.
    Cancer Res. 2022 Aug 29. pii: 708925. doi: 10.1158/0008-5472.CAN-22-0909.
    >> Share

  125. NANDI A, Debnath R, Nayak A, To TKJ, et al
    Dll1-mediated Notch signaling drives tumor cell crosstalk with cancer associated fibroblasts to promote radioresistance in breast cancer.
    Cancer Res. 2022 Aug 24. pii: 708708. doi: 10.1158/0008-5472.CAN-21-1225.
    >> Share

  126. ZENG E, He W, Sjolander A, Bergqvist J, et al
    Determinants and effectiveness of extending the duration of adjuvant hormone therapy beyond 5 years in breast cancer patients.
    Cancer Res. 2022 Aug 18. pii: 708038. doi: 10.1158/0008-5472.CAN-22-0900.
    >> Share

  127. MOASSER MM
    Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions.
    Cancer Res. 2022;82:2811-2820.
    >> Share

  128. ALTWEGG KA, Viswanadhapalli S, Mann M, Chakravarty D, et al
    A first-in-class inhibitor of ER coregulator PELP1 targets ER+ breast cancer.
    Cancer Res. 2022 Aug 11. pii: 707658. doi: 10.1158/0008-5472.CAN-22-0698.
    >> Share

  129. NARDONE A, Qiu X, Spisak S, Nagy Z, et al
    A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer.
    Cancer Res. 2022 Aug 11. pii: 707656. doi: 10.1158/0008-5472.CAN-21-3186.
    >> Share

  130. WU C, Jarrett AM, Zhou Z, Elshafeey N, et al
    MRI-based digital models forecast patient-specific treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer.
    Cancer Res. 2022 Aug 1. pii: 707362. doi: 10.1158/0008-5472.CAN-22-1329.
    >> Share

    July 2022
  131. TIMPERI E, Gueguen P, Molgora M, Magagna I, et al
    Lipid-associated macrophages are induced by cancer-associated fibroblasts and mediate immune suppression in breast cancer.
    Cancer Res. 2022 Jul 21. pii: 707127. doi: 10.1158/0008-5472.CAN-22-1427.
    >> Share

  132. CHEN F, Park SL, Wilkens LR, Wan P, et al
    Genetic Risk of Second Primary Cancer in Breast Cancer Survivors: The Multiethnic Cohort Study.
    Cancer Res. 2022 Jul 14. pii: 707009. doi: 10.1158/0008-5472.CAN-21-4461.
    >> Share

    June 2022
  133. KALRA R, Chen CH, Wang J, Salam AB, et al
    Poziotinib inhibits HER2 mutant-driven therapeutic resistance and multi-organ metastasis in breast cancer.
    Cancer Res. 2022 Jun 23. pii: 705013. doi: 10.1158/0008-5472.CAN-21-3106.
    >> Share

  134. CLARIDGE SE, Hopkins BD
    PI3King the Environment for Growth: PI3K Activation Drives Transcriptome Changes That Support Oncogenic Growth.
    Cancer Res. 2022;82:2216-2218.
    >> Share

  135. LADEWIG E, Michelini F, Jhaveri K, Castel P, et al
    The Oncogenic PI3K-Induced Transcriptomic Landscape Reveals Key Functions in Splicing and Gene Expression Regulation.
    Cancer Res. 2022;82:2269-2280.
    >> Share

  136. ZHANG Z, Golomb L, Meyerson M
    Functional Genomic Analysis of CDK4 and CDK6 Gene Dependency across Human Cancer Cell Lines.
    Cancer Res. 2022;82:2171-2184.
    >> Share

    May 2022
  137. KOPANJA D, Chand V, O'Brien EM, Mukhopadhyay NK, et al
    Transcriptional repression by FoxM1 suppresses tumor differentiation and promotes metastasis of breast cancer.
    Cancer Res. 2022 May 18. pii: 699021. doi: 10.1158/0008-5472.CAN-22-0410.
    >> Share

  138. WEI YT, Wang XR, Yan C, Huang F, et al
    Thymosin alpha-1 Reverses M2 Polarization of Tumor-Associated Macrophages during Efferocytosis.
    Cancer Res. 2022;82:1991-2002.
    >> Share

  139. FATHERREE JP, Guarin JR, McGinn RA, Naber SP, et al
    Chemotherapy-Induced Collagen IV Drives Cancer Cell Motility through Activation of Src and Focal Adhesion Kinase.
    Cancer Res. 2022;82:2031-2044.
    >> Share

  140. MARCZYK M, Gunasekharan V, Casadevall D, Qing T, et al
    Comprehensive Analysis of Metabolic Isozyme Targets in Cancer.
    Cancer Res. 2022;82:1698-1711.
    >> Share

    April 2022
  141. RODRIGUEZ-TIRADO C, Kale N, Carlini MJ, Shrivastava N, et al
    NR2F1 is a barrier to dissemination of early stage breast cancer cells.
    Cancer Res. 2022 Apr 26. pii: 694636. doi: 10.1158/0008-5472.CAN-21-4145.
    >> Share

  142. SINGH S, Lee N, Pedroza DA, Bado IL, et al
    Chemotherapy coupled to macrophage inhibition induces T-cell and B-cell infiltration and durable regression in triple-negative breast cancer.
    Cancer Res. 2022 Apr 20. pii: 694629. doi: 10.1158/0008-5472.CAN-21-3714.
    >> Share

  143. QUIROS-GONZALEZ I, Tomaszewski MR, Golinska MA, Brown E, et al
    Photoacoustic Tomography Detects Response and Resistance to Bevacizumab in Breast Cancer Mouse Models.
    Cancer Res. 2022;82:1658-1668.
    >> Share

  144. PELLEGRINO B, Herencia-Ropero A, Llop-Guevara A, Pedretti F, et al
    Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.
    Cancer Res. 2022;82:1646-1657.
    >> Share

  145. WANG H, Xu H, Chen W, Cheng M, et al
    Rab13 sustains breast cancer stem cells by supporting tumor-stroma crosstalk.
    Cancer Res. 2022 Apr 8. pii: 694330. doi: 10.1158/0008-5472.CAN-21-4097.
    >> Share

  146. ELWAKEEL E, Bruggemann M, Wagih J, Lityagina O, et al
    Disruption of Prostaglandin E2 Signaling in Cancer-Associated Fibroblasts Limits Mammary Carcinoma Growth but Promotes Metastasis.
    Cancer Res. 2022;82:1380-1395.
    >> Share

  147. HONG Z, Liu T, Wan L, Fa P, et al
    Targeting Squalene Epoxidase Interrupts Homologous Recombination via the ER Stress Response and Promotes Radiotherapy Efficacy.
    Cancer Res. 2022;82:1298-1312.
    >> Share

    March 2022
  148. SAMANTA D, Park Y, Andrabi SA, Shelton LM, et al
    Correction: PHGDH Expression Is Required for Mitochondrial Redox Homeostasis, Breast Cancer Stem Cell Maintenance, and Lung Metastasis.
    Cancer Res. 2022;82:1153.
    >> Share

  149. WILSON Z, Odedra R, Wallez Y, Wijnhoven PWG, et al
    ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.
    Cancer Res. 2022;82:1140-1152.
    >> Share

  150. GILKES DM, Chaturvedi P, Bajpai S, Wong CC, et al
    Editor's Note: Collagen Prolyl Hydroxylases Are Essential for Breast Cancer Metastasis.
    Cancer Res. 2022;82:943.
    >> Share

    February 2022
  151. BHATIA S, Kramer M, Russo S, Naik P, et al
    Patient-derived triple-negative breast cancer organoids provide robust model systems that recapitulate tumor-intrinsic characteristics.
    Cancer Res. 2022 Feb 18. pii: 681619. doi: 10.1158/0008-5472.CAN-21-2807.
    >> Share

  152. CHU W, Zhang X, Qi L, Fu Y, et al
    Correction: The EZH2-PHACTR2-AS1- Ribosome Axis Induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer.
    Cancer Res. 2022;82:735.
    >> Share

  153. SCHEIDMANN MC, Castro-Giner F, Strittmatter K, Krol I, et al
    An In Vivo CRISPR Screen Identifies Stepwise Genetic Dependencies of Metastatic Progression.
    Cancer Res. 2022;82:681-694.
    >> Share

  154. LIAO C, Glodowski CR, Fan C, Liu J, et al
    Integrated Metabolic Profiling and Transcriptional Analysis Reveals Therapeutic Modalities for Targeting Rapidly Proliferating Breast Cancers.
    Cancer Res. 2022;82:665-680.
    >> Share

  155. BOONEN RACM, Wiegant WW, Celosse N, Vroling B, et al
    Functional Analysis Identifies Damaging CHEK2 Missense Variants Associated with Increased Cancer Risk.
    Cancer Res. 2022;82:615-631.
    >> Share

  156. LI XQ, Zhang R, Lu H, Yue XM, et al
    Extracellular vesicle-packaged CDH11 and ITGA5 induce the premetastatic niche for bone colonization of breast cancer cells.
    Cancer Res. 2022 Feb 11. pii: 0008-5472.CAN-21-1331.
    >> Share

    January 2022
  157. LI Z, Wu Y, Yates ME, Tasdemir N, et al
    Hotspot ESR1 mutations are multimodal and contextual modulators of breast cancer metastasis.
    Cancer Res. 2022 Jan 25. pii: 0008-5472.CAN-21-2576.
    >> Share

  158. MAJORINI MT, Colombo MP, Lecis D
    Few, but efficient: the role of mast cells in breast cancer and other solid tumors.
    Cancer Res. 2022 Jan 19. pii: 0008-5472.CAN-21-3424.
    >> Share

  159. HAJ-SHOMALY J, Vorontsova A, Barenholz-Cohen T, Levi-Galibov O, et al
    T Cells Promote Metastasis by Regulating Extracellular Matrix Remodeling following Chemotherapy.
    Cancer Res. 2022;82:278-291.
    >> Share

  160. ZHU WJ, Chen X, Guo XY, Liu HT, et al
    Low glucose-induced overexpression of HOXC-AS3 promotes metabolic reprogramming of breast cancer.
    Cancer Res. 2022 Jan 14. pii: 0008-5472.CAN-21-1179.
    >> Share

    December 2021
  161. XU Y, Ren W, Li Q, Duan C, et al
    LncRNA Uc003xsl.1-mediated activation of the NF-kappaB/IL8 axis promotes progression of triple-negative breast cancer.
    Cancer Res. 2021 Dec 29. pii: 0008-5472.CAN-21-1446.
    >> Share

  162. BEETHAM H, Griffith BGC, Murina O, Loftus AE, et al
    Loss of Integrin-linked kinase sensitizes breast cancer to SRC inhibitors.
    Cancer Res. 2021 Dec 17. pii: 0008-5472.CAN-21-0373.
    >> Share

  163. OBA T, Kajihara R, Yokoi T, Repasky EA, et al
    Neoadjuvant In Situ Immunomodulation Enhances Systemic Antitumor Immunity against Highly Metastatic Tumors.
    Cancer Res. 2021;81:6183-6195.
    >> Share

  164. MOORE J, Ma L, Lazar A, Barcellos-Hoff MH, et al
    Mammary tumor-derived transplants as breast cancer models to evaluate tumor-immune interactions and therapeutic responses.
    Cancer Res. 2021 Dec 13. pii: 0008-5472.CAN-21-0253.
    >> Share

    November 2021
  165. CHOI SR, Hwang CY, Lee J, Cho KH, et al
    Network Analysis Identifies Regulators of Basal-Like Breast Cancer Reprogramming and Endocrine Therapy Vulnerability.
    Cancer Res. 2021 Nov 29. pii: 0008-5472.CAN-21-0621.
    >> Share

  166. YUAN H, Yan L, Wu M, Shang Y, et al
    Analysis of the estrogen receptor-associated lncRNA landscape identifies a role for ERLC1 in breast cancer progression.
    Cancer Res. 2021 Nov 22. pii: 0008-5472.CAN-21-1155.
    >> Share

  167. SUBRAMANIAN S, Daquinag AC, AghaAmiri S, Ghosh SC, et al
    Characterization of Peptides Targeting Metastatic Tumor Cells as Probes for Cancer Detection and Vehicles for Therapy Delivery.
    Cancer Res. 2021;81:5756-5764.
    >> Share

  168. JANJANAM J, Pano G, Wang R, Minden-Birkenmaier BA, et al
    Matricellular Protein WISP2 Is an Endogenous Inhibitor of Collagen Linearization and Cancer Metastasis.
    Cancer Res. 2021;81:5666-5677.
    >> Share

  169. XING F, Liu Y, Wu SY, Wu K, et al
    Correction: Loss of XIST in Breast Cancer Activates MSN-c-Met and Reprograms Microglia via Exosomal miRNA to Promote Brain Metastasis.
    Cancer Res. 2021;81:5582.
    >> Share

  170. DAMODARAN S, Hortobagyi GN
    Estrogen Receptor: A Paradigm for Targeted Therapy.
    Cancer Res. 2021;81:5396-5398.
    >> Share

  171. GRISARU-TAL S, Dulberg S, Beck L, Zhang C, et al
    Metastasis-Entrained Eosinophils Enhance Lymphocyte-Mediated Antitumor Immunity.
    Cancer Res. 2021;81:5555-5571.
    >> Share

  172. TEMPS C, Lietha D, Webb ER, Li XF, et al
    A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability.
    Cancer Res. 2021;81:5438-5450.
    >> Share

  173. HINSHAW DC, Hanna A, Lama-Sherpa T, Metge B, et al
    Hedgehog Signaling Regulates Metabolism and Polarization of Mammary Tumor-Associated Macrophages.
    Cancer Res. 2021;81:5425-5437.
    >> Share

    October 2021
  174. PATEL A, Garcia-Closas M, Olshan AF, Perou CM, et al
    Gene level germline contributions to clinical risk of recurrence scores in Black and White breast cancer patients.
    Cancer Res. 2021 Oct 28. pii: 0008-5472.CAN-21-1207.
    >> Share

  175. DONE SJ, Kanwar N, Balde Z, Nair R, et al
    Heterogeneity of circulating tumor cell-associated genomic gains in breast cancer and its association with the host immune response.
    Cancer Res. 2021 Oct 28. pii: 0008-5472.CAN-21-1079.
    >> Share

  176. GOU X, Anurag M, Lei JT, Kim BJ, et al
    Transcriptional reprogramming differentiates active from inactive ESR1 fusions in endocrine therapy-refractory metastatic breast cancer.
    Cancer Res. 2021 Oct 28. pii: 0008-5472.CAN-21-1256.
    >> Share

  177. HUGGINS DN, LaRue RS, Wang Y, Knutson TP, et al
    Characterizing Macrophage Diversity in Metastasis-Bearing Lungs Reveals a Lipid-Associated Macrophage Subset.
    Cancer Res. 2021;81:5284-5295.
    >> Share

  178. WOITEK R, McLean MA, Ursprung S, Rueda OM, et al
    Hyperpolarized carbon-13 MRI for early response assessment of neoadjuvant chemotherapy in breast cancer patients.
    Cancer Res. 2021 Oct 8. pii: 0008-5472.CAN-21-1499.
    >> Share

    September 2021
  179. LIU C, Qiang J, Deng Q, Xia J, et al
    ALDH1A1 activity in tumor-initiating cells remodels myeloid-derived suppressor cells to promote breast cancer progression.
    Cancer Res. 2021 Sep 27. pii: 0008-5472.CAN-21-1337.
    >> Share

  180. ZHAO X, Li J, Liu Z, Powers S, et al
    Combinatorial CRISPR/Cas9 Screening Reveals Epistatic Networks of Interacting Tumor Suppressor Genes and Therapeutic Targets in Human Breast Cancer.
    Cancer Res. 2021 Sep 24. pii: 0008-5472.CAN-21-2555.
    >> Share

  181. ANSARI KI, Bhan A, Saotome M, Tyagi A, et al
    Autocrine GMCSF Signaling Contributes to Growth of HER2(+) Breast Leptomeningeal Carcinomatosis.
    Cancer Res. 2021;81:4723-4735.
    >> Share

  182. FAURE C, Djerbi-Bouillie R, Domingot A, Bouzinba-Segard H, et al
    Allosteric inhibition of HER2 by Moesin-mimicking compounds targets HER2-positive cancers and brain metastases.
    Cancer Res. 2021 Sep 7. pii: 0008-5472.CAN-21-0162.
    >> Share

    August 2021
  183. PULEO J, Polyak K
    The MCF10 Model of Breast Tumor Progression.
    Cancer Res. 2021;81:4183-4185.
    >> Share

  184. APOSTOLIDI M, Vathiotis IA, Muthusamy V, Gaule P, et al
    Targeting Pyruvate Kinase M2 Phosphorylation Reverses Aggressive Cancer Phenotypes.
    Cancer Res. 2021;81:4346-4359.
    >> Share

    July 2021
  185. TAKAYAMA KI, Honma T, Suzuki T, Kondoh Y, et al
    Targeting Epigenetic and Posttranscriptional Gene Regulation by PSF Impairs Hormone Therapy-Refractory Cancer Growth.
    Cancer Res. 2021;81:3495-3508.
    >> Share

  186. STEINER MC, Marston JL, Iniguez LP, Bendall ML, et al
    Locus-Specific Characterization of Human Endogenous Retrovirus Expression in Prostate, Breast, and Colon Cancers.
    Cancer Res. 2021;81:3449-3460.
    >> Share

  187. CHOI H, Kwon J, Cho MS, Sun Y, et al
    Targeting DDX3X Triggers Antitumor Immunity via a dsRNA-Mediated Tumor-Intrinsic Type I Interferon Response.
    Cancer Res. 2021;81:3607-3620.
    >> Share

  188. YOO KH, Tang JJ, Rashid MA, Cho CH, et al
    Nicotinamide Mononucleotide Prevents Cisplatin-Induced Cognitive Impairments.
    Cancer Res. 2021;81:3727-3737.
    >> Share

    June 2021
  189. BHAN A, Ansari KI, Chen MY, Jandial R, et al
    Inhibition of Jumonji Histone Demethylases Selectively Suppresses HER2(+) Breast Leptomeningeal Carcinomatosis Growth via Inhibition of GMCSF Expression.
    Cancer Res. 2021;81:3200-3214.
    >> Share

  190. ZHOU Q, Howard ME, Tu X, Zhu Q, et al
    Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining.
    Cancer Res. 2021;81:3333-3346.
    >> Share

    May 2021
  191. YANG B, Li X, Fu Y, Guo E, et al
    MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors.
    Cancer Res. 2021;81:2714-2729.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016